Dogwood Therapeutics Doses First Patient in Clinical Trial
ATLANTA — Dogwood Therapeutics, Inc. (Nasdaq: DWTX), a biopharmaceutical company dedicated to developing innovative non-opioid treatments for pain, has commenced dosing in its Phase 2b clinical trial. This trial, named HALT-CINP, focuses on evaluating Halneuron® for patients suffering from chemotherapy-induced neuropathic pain, commonly referred to as CINP.
About Halneuron® and Its Potential
Halneuron® is a pioneering treatment designed to specifically target the NaV 1.7 sodium channel, a key player in pain transmission. Greg Duncan, the Chairman and CEO of Dogwood, has emphasized that the precise and potent nature of Halneuron® could allow for lower dosages while still effectively managing pain and minimizing unwanted side effects typically associated with other NaV 1.7 development candidates.
Clinical Background and Efficacy
Halneuron® has shown promise in previous studies, achieving a statistically significant reduction in cancer pain during an earlier Phase 2 clinical trial, while also maintaining a favorable safety profile. To date, over 700 patients have been evaluated across various Phase 1 and Phase 2 studies, with no evidence of addiction potential linked to its use.
Trial Objectives and Future Plans
The current goal for Dogwood is to recruit 100 patients for this trial by the end of 2025, which will facilitate an interim analysis of the HALT-CINP trial around the same time. Dr. R. Michael Gendreau, Dogwood’s Chief Medical Officer, highlighted that this analysis will help refine the trial design as necessary to enhance overall outcomes.
Overview of Dogwood's Research Pipeline
As a company in the development stage, Dogwood Therapeutics is dedicated to creating new therapies for pain and disorders related to fatigue. Its research pipeline encompasses two distinct platforms: one focused on non-opioid analgesics and another on antiviral therapies. The lead candidate in the non-opioid analgesic program is Halneuron®, recognized for its effectiveness in altering how pain is transmitted in clinical settings.
Advancements in Antiviral Therapies
In addition to Halneuron®, Dogwood is advancing an antiviral program that features IMC-1 and IMC-2, which consist of fixed-dose combinations of anti-herpes antivirals paired with celecoxib, an anti-inflammatory agent. These innovative combinations target conditions believed to be associated with the reactivation of dormant herpesviruses, including fibromyalgia and Long-COVID. IMC-1 is expected to progress to Phase 3 as a treatment for fibromyalgia, while IMC-2 has been subjected to rigorous testing, demonstrating the reduction of fatigue related to Long-COVID.
Regulatory Progress
Dogwood has engaged with the FDA to establish fatigue reduction as a primary endpoint for its future research into Long-COVID, with plans well underway to advance IMC-2 into further Phase 2b studies.
Learn More About Dogwood Therapeutics
For additional insights into Dogwood Therapeutics and their innovative projects, please visit their official website. Here you can find comprehensive information about their clinical trials and upcoming developments in the field of pain management.
Frequently Asked Questions
What is Halneuron® and what does it aim to treat?
Halneuron® is a pain treatment that specifically targets the NaV 1.7 sodium channel to help manage neuropathic pain resulting from chemotherapy.
How many patients does Dogwood plan to recruit for its trial?
Dogwood aims to recruit 100 patients with chemotherapy-induced neuropathic pain for their Phase 2b trial.
What previous results have been observed with Halneuron®?
In past clinical trials, Halneuron® has shown significant reductions in cancer-related pain with an acceptable safety profile.
How is Dogwood's antiviral program related to herpesviruses?
Dogwood’s antiviral program targets conditions believed to be linked to dormant herpesvirus reactivation, including fibromyalgia and Long-COVID.
Where can I find more information about Dogwood Therapeutics?
More information can be found on Dogwood's official website, which provides details on their trials and research initiatives.
